Telomium
Develops ribonucleoprotein-based cancer immunotherapies for patients with cancer
Highlights
- New on EvolcAdded 2026-11-14
About Telomium
Telomium is a biotechnology company developing ribonucleoprotein-based immunotherapies. Its lead product, TLVX01, targets telomerase, and its pipeline includes oncology and other immunotherapy products.
The company reports preclinical activity in dogs with spontaneous tumors. It is based in Ivry-sur-Seine, France, and was founded in 2016.
Product: Ribonucleoprotein-based immunotherapies, including the telomerase-targeting lead product TLVX01.
Jobs at Telomium
Leadership
- Guillaume Kellermann · President & FounderSource: company website
More biotech & pharma companies
Temisis
Develops preclinical small-molecule treatments for inflammatory diseases, including psoriasisNew on EvolcTerratis
Sterile-insect mosquito control services for French municipalities and other high-traffic public areasYoung companyNew on EvolcThea Open Innovation
Ophthalmology innovation partnerships and investment for startups, researchers and companies developing eye-care treatmentsTheranovir
Develops therapies targeting cancer, obesity-related diseases and viral infections for patients and healthcare marketsNew on EvolcTheravectys
Lentiviral vector vaccine candidates for cancers and chronic infectious diseases, developed with Institut PasteurNew on EvolcTissium
Biomorphic programmable polymers for tissue reconstruction in surgery, developed for medtech and surgical use
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.